Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 1/14/2026

Medications That Cause Hyperkalemia

Medications That Decrease Potassium Excretion

  • The European Society of Cardiology recommends that ACE inhibitors (e.g., lisinopril, enalapril) and angiotensin receptor blockers (ARBs) (e.g., losartan, valsartan) be used with caution due to their potential to cause hyperkalemia 1, 2
  • Mineralocorticoid receptor antagonists (MRAs) (e.g., spironolactone, eplerenone) and direct renin inhibitors (e.g., aliskiren) can also cause hyperkalemia, especially when combined with other medications 1, 2
  • Sacubitril/valsartan, a combination of a neprilysin inhibitor and an ARB, can also increase the risk of hyperkalemia 1, 2
  • Triamterene and amiloride, both potassium-sparing diuretics, can cause hyperkalemia, especially when used in combination with other medications 1, 2
  • Calcineurin inhibitors (e.g., cyclosporine, tacrolimus) and trimethoprim-sulfamethoxazole can also increase the risk of hyperkalemia 1, 2
  • Digitalis and mannitol can cause hyperkalemia, especially when used in high doses or in combination with other medications 1, 2
  • Penicillin G, when used in high doses, can also increase the risk of hyperkalemia 1, 2

Medications That Increase Potassium Intake/Administration

  • Potassium supplements and salt substitutes (e.g., those used in the DASH diet) can increase the risk of hyperkalemia, especially when used in combination with other medications 1, 2
  • Stored blood products and certain herbal supplements, including alfalfa, dandelion, and hawthorne berry, can also increase the risk of hyperkalemia 1, 2
  • Amino acids (e.g., aminocaproic acid, arginine, lysine) can cause hyperkalemia, especially when used in high doses or in combination with other medications 1, 2

Prevention Strategies

  • The European Society of Cardiology recommends using the lowest effective dose of medications known to cause hyperkalemia and considering the use of loop or thiazide diuretics concurrently with RAAS inhibitors to reduce hyperkalemia risk 1
  • Educating patients about dietary sources of potassium that should be limited can also help prevent hyperkalemia 1, 2

Medications That Cause Hyperkalemia

Medications That Decrease Potassium Excretion

  • The American College of Cardiology recommends avoiding the combination of direct renin inhibitors, such as aliskiren, with ACE inhibitors or ARBs due to increased hyperkalemia risk, particularly in patients with chronic kidney disease 3
  • The American College of Cardiology suggests that spironolactone and eplerenone, aldosterone antagonists, increase the risk of hyperkalemia when used alone or in combination with RAAS inhibitors, with a dose-dependent effect 3
  • The American College of Cardiology advises against combining RAAS inhibitors with aldosterone antagonists or potassium-sparing diuretics in patients with GFR <45 mL/min unless absolutely necessary, due to a significantly increased risk of hyperkalemia 3
  • Patients with chronic kidney disease (GFR <45 mL/min) are at a 2.47-fold increased risk of developing severe hyperkalemia when using RAAS inhibitors or aldosterone antagonists 3

High-Risk Clinical Scenarios

  • The combination of spironolactone with ACE inhibitors or ARBs carries a high risk of hyperkalemia, with a reported mean serum potassium of 7.7 mmol/L on admission, requiring hemodialysis in 68% of cases and ICU admission in 48% 3

Monitoring and Prevention Strategies

  • The American College of Cardiology recommends monitoring serum potassium within 1 week of initiating or titrating any RAAS inhibitor or aldosterone antagonist, then regularly thereafter, to prevent hyperkalemia 3
  • The American College of Cardiology advises against exceeding spironolactone 25 mg daily when combined with RAAS inhibitors, and considers adding loop or thiazide diuretics to promote potassium excretion when using RAAS inhibitors 3
  • The American College of Cardiology recommends avoiding the combination of aliskiren with ACE inhibitors or ARBs due to excessive hyperkalemia risk 3

Medications That Contribute to Hyperkalemia

Primary Causes of Hyperkalemia

  • The American Academy of Pediatrics recommends monitoring serum potassium and creatinine periodically to prevent hyperkalemia when using ACE inhibitors like lisinopril 4
  • The use of ACE inhibitors like lisinopril can impair renal potassium excretion by blocking aldosterone production, making them a common drug-related cause of hyperkalemia 4
  • Loop diuretics like bumetanide can mitigate hyperkalemia risk from RAAS inhibitors, but intermittent dosing may provide insufficient kaliuresis, allowing potassium accumulation 5, 6

Aggravating Factors

  • The combination of ACE inhibitors with potassium supplements creates an additive hyperkalemia risk and should be avoided unless there is documented refractory hypokalemia 4
  • Inadequate diuretic coverage, such as bumetanide only three times weekly, can contribute to hyperkalemia risk by allowing potassium accumulation 5

Management and Prevention

  • The FDA recommends checking serum potassium and creatinine frequently when concomitant use of ACE inhibitors and potassium-sparing diuretics or supplements is indicated 4
  • Consider increasing bumetanide frequency to daily dosing or adding a thiazide diuretic to promote potassium excretion 5

Medication-Induced Hyperkalemia

Primary Medications That Decrease Potassium Excretion

  • The American College of Cardiology recommends that ACE inhibitors, such as lisinopril, enalapril, captopril, and ramipril, be used with caution as they can cause hyperkalemia by blocking aldosterone production and impairing renal potassium excretion, with up to 10% of patients experiencing at least mild hyperkalemia 7
  • The American College of Cardiology also notes that ARBs, such as losartan, valsartan, candesartan, and olmesartan, carry equivalent hyperkalemia risk to ACE inhibitors through the same mechanism of aldosterone suppression 7
  • The American Heart Association recommends that direct renin inhibitors, such as aliskiren, should never be combined with ACE inhibitors or ARBs due to excessive hyperkalemia risk, particularly in patients with chronic kidney disease 7
  • The American College of Cardiology states that spironolactone and eplerenone can cause hyperkalemia in 2-5% of clinical trial patients but up to 24-36% in real-world practice, with risk increasing progressively when serum creatinine exceeds 1.6 mg/dL 8, 9
  • The American Heart Association advises that the combination of spironolactone with ACE inhibitors or ARBs is particularly dangerous and should be avoided 8
  • The American College of Cardiology recommends that spironolactone doses should not exceed 25 mg daily when combined with RAAS inhibitors, and should be initiated at 12.5 mg in patients with marginal renal function (GFR 30-49 mL/min) 8
  • The American Heart Association states that the triple combination of ACE inhibitor + ARB + aldosterone antagonist should be avoided entirely 8
  • The American College of Cardiology notes that amiloride and triamterene directly block potassium excretion in the collecting duct and carry significant hyperkalemia risk, especially when combined with RAAS inhibitors 7

Monitoring and Prevention Strategies

  • The American Heart Association recommends checking potassium and creatinine within 2-3 days, again at 7 days, then monthly for 3 months after initiating or increasing doses of RAAS inhibitors or aldosterone antagonists 8
  • The American College of Cardiology advises discontinuing or reducing potassium supplements when starting aldosterone antagonists 8, 9
  • The American Heart Association recommends avoiding NSAIDs and COX-2 inhibitors in patients on RAAS inhibitors, as they further impair renal potassium excretion 9
  • The American College of Cardiology states that aldosterone antagonists should not be initiated when baseline potassium exceeds 5.0 mEq/L or creatinine exceeds 2.5 mg/dL in men or 2.0 mg/dL in women (GFR <30 mL/min) 8, 9

Management When Hyperkalemia Develops

  • The American Heart Association recommends that potassium >5.5 mEq/L should trigger discontinuation or dose reduction of the offending agent unless other reversible causes are identified 8

Management of Hyperkalemia Risk with RAAS‑Targeted Therapies and Concomitant Medications

Incidence of Hyperkalemia with Aldosterone Antagonists

  • In clinical trials, aldosterone antagonists (e.g., spironolactone, eplerenone) cause hyperkalemia in approximately 2–5 % of patients, whereas real‑world practice reports rates of 24–36 %; the risk rises markedly when baseline serum creatinine exceeds 1.6 mg/dL. 10

High‑Risk Drug Combinations

  • Combining an aldosterone antagonist with an ACE inhibitor or ARB markedly increases serum potassium (mean ≈ 7.7 mmol/L on admission), leading to dialysis in ≈ 68 % of cases and ICU admission in ≈ 48 % of patients. 10
  • The triple regimen of an ACE inhibitor + ARB + aldosterone antagonist should be avoided because of a substantially elevated hyperkalemia risk. 10
  • Co‑administration of trimethoprim‑sulfamethoxazole with an ACE inhibitor or ARB in patients with reduced kidney function significantly raises the likelihood of hyperkalemia. 11

Monitoring Recommendations After Initiating RAAS‑Modifying Therapy

  • Serum potassium and creatinine should be measured 2–3 days after starting or up‑titrating a RAAS inhibitor or aldosterone antagonist, repeated at 7 days, and then monthly for the first 3 months. 10
  • Aldosterone antagonists should not be initiated when baseline serum potassium exceeds 5.0 mEq/L. 10

Additional Medications That Impair Renal Potassium Excretion

  • Non‑steroidal anti‑inflammatory drugs (NSAIDs) reduce aldosterone secretion and promote sodium retention, thereby impairing renal potassium excretion. 10

Patient Populations at Highest Risk

  • Older adults (age > 50 years) on multiple medications have a heightened susceptibility to drug‑induced hyperkalemia. 10
  • Patients with renal impairment (serum creatinine > 1.6 mg/dL) are at increased risk for hyperkalemia when receiving RAAS‑targeted drugs. 10

Trimethoprim‑Sulfamethoxazole–Induced Hyperkalemia

  • Trimethoprim‑sulfamethoxazole blocks epithelial sodium channels in the distal nephron, mimicking the effect of potassium‑sparing diuretics and causing hyperkalemia, especially when combined with ACE inhibitors or ARBs. 11

REFERENCES

← Return to Home